×
About 5,973 results

ALLMedicine™ Leukemias Center

Research & Reviews  1,811 results

Abnormal monocyte differentiation and function in chronic myelomonocytic leukemia.
https://doi.org/10.1097/MOH.0000000000000689
Current Opinion in Hematology; Dhawan A, Padron E

Dec 3rd, 2021 - Monocytes serve as the phagocytic defense surveillance system of the human body. Although there is comprehensive evidence regarding monocyte development, characterization and function under steady state hematopoietic continuum, the deviations and ...

Phase I Study of Anti-CD22 Chimeric Receptor T Cells in Patients With Relapsed/Refractory Hairy Cell Leukemia and Variant
https://clinicaltrials.gov/ct2/show/NCT04815356

Dec 3rd, 2021 - Background Hairy cell leukemia (HCL) is an indolent CD22+ B-cell leukemia comprising 2% of all leukemias. Most cases of HCL respond well to purine analog chemotherapy and harbor BRAF V600E mutation that can be considered for targeted treatment at ...

Feedback Loop Regulation Between Pim Kinases and Tax Keeps HTLV-I Viral Replication in ...
https://doi.org/10.1128/JVI.01960-21
Journal of Virology; Bellon M, Nicot C

Nov 25th, 2021 - The Pim family of serine/threonine kinases promote tumorigenesis by enhancing cell survival and inhibiting apoptosis. Three isoforms exist, Pim-1, -2, and -3 that are highly expressed in hematological cancers, including Pim-1 in Adult T-cell leuke...

PLX3397 in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN)
https://clinicaltrials.gov/ct2/show/NCT02390752

Nov 24th, 2021 - Background Traditional therapeutic approaches to pediatric cancer have focused on cytotoxic agents and, more recently, targeted inhibition of cellular signaling pathways through the use of small molecule kinase inhibitors. Despite these interventi...

A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat
https://clinicaltrials.gov/ct2/show/NCT04726241

Nov 19th, 2021 - PRIMARY OBJECTIVES: I. To utilize clinical and biological characteristics of acute leukemias to screen for patient eligibility for available phase I/II Pediatric Acute Leukemia (PedAL) sub-trials. II. To maintain a longitudinal and comprehensive r...

see more →

Guidelines  2 results

Hairy Cell Leukemia, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology.
https://doi.org/10.6004/jnccn.2017.0165
Journal of the National Comprehensive Cancer Network : JN... Wierda WG, Byrd JC et. al.

Nov 10th, 2017 - Hairy cell leukemia (HCL) is a rare type of indolent B-cell leukemia, characterized by symptoms of fatigue and weakness, organomegaly, pancytopenia, and recurrent opportunistic infections. Classic HCL should be considered a distinct clinical entit...

Acute Myeloid Leukemia, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology.
https://doi.org/10.6004/jnccn.2017.0116
Journal of the National Comprehensive Cancer Network : JN... O'Donnell MR, Tallman MS et. al.

Jul 9th, 2017 - Acute myeloid leukemia (AML) is the most common form of acute leukemia among adults and accounts for the largest number of annual deaths due to leukemias in the United States. This portion of the NCCN Guidelines for AML focuses on management and p...

see more →

Drugs  214 results see all →

Clinicaltrials.gov  82 results

Phase I Study of Anti-CD22 Chimeric Receptor T Cells in Patients With Relapsed/Refractory Hairy Cell Leukemia and Variant
https://clinicaltrials.gov/ct2/show/NCT04815356

Dec 3rd, 2021 - Background Hairy cell leukemia (HCL) is an indolent CD22+ B-cell leukemia comprising 2% of all leukemias. Most cases of HCL respond well to purine analog chemotherapy and harbor BRAF V600E mutation that can be considered for targeted treatment at ...

PLX3397 in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN)
https://clinicaltrials.gov/ct2/show/NCT02390752

Nov 24th, 2021 - Background Traditional therapeutic approaches to pediatric cancer have focused on cytotoxic agents and, more recently, targeted inhibition of cellular signaling pathways through the use of small molecule kinase inhibitors. Despite these interventi...

A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat
https://clinicaltrials.gov/ct2/show/NCT04726241

Nov 19th, 2021 - PRIMARY OBJECTIVES: I. To utilize clinical and biological characteristics of acute leukemias to screen for patient eligibility for available phase I/II Pediatric Acute Leukemia (PedAL) sub-trials. II. To maintain a longitudinal and comprehensive r...

A Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Activity of Idasanutlin in Combination With Either Chemotherapy or Venetoclax in the Treatment of Pediatric and Young ...
https://clinicaltrials.gov/ct2/show/NCT04029688

Nov 3rd, 2021 - This is a Phase I/II, multicenter, open-label, multi-arm study designed to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of idasanutlin, administered as a single agent or in combination with chemotherapy or venetocl...

GNR-084 Safety and Pharmacological Characteristics in Refractory or Relapse B-cell Precursor ALL
https://clinicaltrials.gov/ct2/show/NCT04601584

Oct 26th, 2021 - Acute lymphoblastic leukemias (ALL) are a heterogeneous group of malignant clonal diseases of the blood system originating from precursor cells of hematopoiesis, predominantly of lymphoid differentiation. More than 7,200 new cases of ALL are diagn...

see more →

News  279 results

New Trials in Leukemia: Could Your Patient Benefit?
https://www.medscape.com/viewarticle/962196

Nov 3rd, 2021 - A number of late-phase clinical trials in leukemia have opened in recent months. Maybe one of your patients could benefit from being enrolled. Adults and Children With Acute or Chronic Leukemias A phase 2 study partnering with the National Marrow ...

Trial Aims to Match Pediatric Patients With More Precise Leukemia Therapy
https://www.onclive.com/view/trial-aims-to-match-pediatric-patients-with-more-precise-leukemia-therapy

Oct 6th, 2021 - Yana Pikman, MD An advanced understanding of the biology of hematologic malignancies has significantly improved survival outcomes. However, in pediatric acute leukemias, said Yana Pikman, MD, the integration of real-time genomic sequencing data i...

Bringing Epigenetic Therapies From Bench to Bedside
https://www.onclive.com/view/bringing-epigenetic-therapies-from-bench-to-bedside

Oct 6th, 2021 - Ronan T. Swords, MD, PhD Pap Corps Endowed Professor in Leukemia Sylvester Comprehensive Cancer Center University of Miami Miller School of Medicine Miami, FL Although there have been advances in therapeutics and supportive care, the...

Alpha-Particle Radiopharmaceuticals Moving Forward as AML Therapy
https://www.onclive.com/view/alpha-particle-radiopharmaceuticals-moving-forward-as-aml-therapy

Oct 6th, 2021 - Joseph G. Jurcic, MD Professor, Medicine Columbia University Medical Center Director, Hematologic Malignancies Section Attending Physician, New York-Presbyterian Hospital Member, Herbert Irving Comprehensive Cancer Center Although st...

Roswell Park Transplant Specialists Explore New Strategies for Tackling GVHD
https://www.onclive.com/view/roswell-park-transplant-specialists-explore-new-strategies-for-tackling-gvhd

Oct 6th, 2021 - Philip McCarthy, MD Director of Transplant and Cellular Therapies Professor of Oncology and Internal Medicine Roswell Park Comprehensive Cancer Center Professor in the Department of Medicine Jacobs School of Medicine and Biomedical Scie...

see more →

Patient Education  1 results see all →